2010 Health

Topics also related to Technology:


FDA seen tougher on drug risks post-Avandia

NEW YORK Regulators appear to be increasing their scrutiny of product risks after cases like the bitter debate over the diabetes pill Avandia, industry executives and experts said this week.

Analysis: Sluggish medical device sector ripe for mergers

NEW YORK The stage is set for more dealmaking in the medical device sector, with companies eager to find faster growth amid a stubbornly weak economy and potential targets still attractively valued.


AstraZeneca CEO wary of U.S. FDA budget cuts

NEW YORK Sharp cuts in taxpayer funding for the U.S. Food and Drug Administration could hurt pharmaceutical companies that want faster reviews of their products, AstraZeneca Plc's chief executive said on Wednesday.


Analysis: Health insurers shake up model after U.S. overhaul

NEW YORK Become tech-savvy. Bulk up. Venture abroad.

Health overhaul should press ahead: industry

NEW YORK Repeal reform? No thanks, say health insurers, drugmakers and others looking for a clearer picture of the U.S. healthcare market after the bruising passage of the controversial overhaul law.

Analysis: Drug industry doses up on emerging markets

NEW YORK Big Pharma's drive into emerging markets could make drugmakers look a lot more like consumer goods companies in future. That may be no bad thing.


Analysis: Americans make slow return to doctor's offices

NEW YORK Americans are slowly making their way back to the doctor's office after many months of skimping on medical care, holding off on everything from routine visits to hip replacements.


New Aetna CEO brings style shift to insurer

NEW YORK Aetna Inc President Mark Bertolini, who becomes CEO later this month, has half the kidneys and twice the energy of an ordinary human being and is set to take on the Herculean task of trying to change the health insurance industry's villainous image. | Video


Health Summit quotes of the day

Following is a selection of quotes from the Reuters Health Summit: | Video


Analysis: Top-name drug recalls a bitter pill for consumers

NEW YORK With bugs in baby formula, glass flakes in intravenous drugs and foul odors emanating from Lipitor and children's Tylenol, a steady stream of high profile product recalls is undermining confidence in top drugmakers.

Analysis: Genzyme seen an anomaly in bite-sized market

NEW YORK Sanofi-Aventis' $18.5 billion pursuit of Genzyme Corp may be a foregone conclusion for many healthcare industry executives and bankers, but few rivals likely will copy the hostile bid.

Topics also related to Technology: